IGIV, also written as IVIG, stands for intravenous immunoglobulin. It’s a medical treatment made from the antibodies of thousands of blood donors, delivered directly into a vein through an IV line. These concentrated antibodies can either replace what your immune system isn’t making on its own or calm an overactive immune response that’s attacking your body. A typical infusion takes about three hours.
How IGIV Works
Your immune system normally produces proteins called immunoglobulins (antibodies) to fight off infections. IGIV is essentially a large dose of one specific type, called IgG, pooled from the plasma of many donors. Because it draws from so many people, the final product contains a broad mix of antibodies capable of recognizing a wide range of bacteria, viruses, and other threats.
IGIV serves two fundamentally different purposes depending on the condition being treated. For people whose immune systems can’t produce enough antibodies on their own, it acts as a direct replacement, filling in the gap so their bodies can fight infections. For people with autoimmune or inflammatory conditions, higher doses of IGIV work differently: they modulate the immune system, essentially dialing down the harmful overreaction without fully suppressing immunity the way some other treatments do.
Conditions Treated With IGIV
The FDA has approved IGIV for several conditions spanning both categories. The most common use is for primary immunodeficiency disorders, where the body doesn’t produce adequate antibodies. This includes conditions like common variable immunodeficiency (CVID), which is the single category with the most approved IGIV products on the market.
Other FDA-approved uses include:
- Immune thrombocytopenia (ITP): a condition where the immune system destroys blood platelets, causing easy bruising and bleeding
- Kawasaki disease: an inflammatory condition in children that affects blood vessels, particularly around the heart
- B-cell chronic lymphocytic leukemia: a type of blood cancer where patients often develop secondary immune deficiencies
- Multifocal motor neuropathy: a nerve disorder causing progressive weakness in the hands and arms
- Bone marrow transplantation: to support immune function during recovery
- HIV infection: to prevent infections in patients with weakened immunity
Beyond these approved uses, doctors frequently prescribe IGIV off-label for a wider range of autoimmune and neurological conditions. This is common in medicine, and many of these off-label uses have significant clinical evidence behind them, even if they haven’t gone through the formal FDA approval process for that specific product.
What an Infusion Is Like
IGIV is given through an IV line, typically in a hospital, infusion center, or sometimes at home with nursing support. The infusion itself generally takes around three hours, though the first session may take longer because the rate is increased gradually to watch for reactions. How often you receive infusions depends on your condition. People receiving replacement therapy for immunodeficiency typically go every three to four weeks for life or as long as the underlying condition persists.
Some patients are given medications before the infusion to reduce the chance of side effects. These premedications typically address pain, fever, and allergic-type symptoms. Your care team will monitor you during and after the infusion, particularly during early treatments when reactions are more likely.
Common and Serious Side Effects
Reactions during or shortly after infusion are relatively common. In a large pediatric study, about 26% of infusions resulted in at least one side effect, and roughly 39% of patients experienced a reaction at some point during treatment. The most frequent issues were fever (about 14% of infusions), headache (about 7%), and a temporary increase in heart rate (about 7%). These reactions are typically mild and manageable.
Serious side effects are rare but worth knowing about. They include severe allergic reactions, a type of non-infectious meningitis that causes intense headaches, destruction of red blood cells, blood clots, and lung-related complications. Blood clots occurred in less than 1% of infusions in clinical data. Higher doses and first-time infusions both independently increase the likelihood of a reaction, so early sessions tend to get the closest monitoring.
IgA Deficiency and Allergy Risk
One specific concern involves people who are deficient in a different type of antibody called IgA. Because IGIV products contain small amounts of IgA, patients who lack it can sometimes develop antibodies against IgA, raising the risk of a severe allergic reaction during infusion. That said, current guidance does not recommend withholding IGIV from IgA-deficient patients when they need it. Products with lower IgA content are available, and doctors can take precautions to reduce risk.
How IGIV Is Made Safe
Because IGIV comes from human blood, the manufacturing process includes multiple safety steps to prevent viral transmission. Donors are screened for infections according to national guidelines, and their plasma is tested for viruses before processing begins. During manufacturing, a chemical precipitation step removes contaminating proteins, aggregates, and viruses. A separate solvent and detergent treatment inactivates additional viral threats. These steps are validated against multiple types of viruses before a product reaches patients.
IGIV vs. Subcutaneous Immunoglobulin
IGIV isn’t the only way to receive immunoglobulin therapy. Subcutaneous immunoglobulin (SCIG) delivers the same antibodies through a small needle just under the skin instead of into a vein. SCIG doesn’t require venous access, causes fewer systemic reactions like fever and headache, and can be self-administered at home, which many patients find more convenient and less disruptive to daily life.
The tradeoff is that SCIG infusions are typically given more frequently, often weekly rather than monthly, and may require multiple injection sites per session. For people with primary immunodeficiency who will be on lifelong therapy, the choice between the two often comes down to lifestyle, tolerance of side effects, and personal preference. Home-based SCIG is associated with improved quality of life for some patients and lower overall healthcare costs compared to hospital-based IVIG infusions. Your doctor can help determine which route makes the most sense for your specific condition and circumstances.